Abstract:Background. Myasthenia gravis (MG) is an acquired autoimmune disease. The main clinical features of MG are skeletal muscle fatigue and pathological fatigue, which worsen at night or after fatigue, such as dyspnea, dysphagia, and systemic weakness. Plasma exchange (PE) is often used in patients with acute exacerbation of MG. Intravenous immunoglobulin (IVIG) is a collection of immunoglobulins from thousands of donors. IVIG can replace a variety of immunosuppressants or PE. However, the effect of PE or IVIG on patients' consciousness, immune function, and prognosis is not clear. Objective. A prospective randomized test of the effects of PE combined with immunoglobulin on consciousness, immune function, and prognosis in patients with myasthenia gravis crisis (MGC). Methods. Sixty patients with MGC treated from February 2019 to April 2021 were enrolled in our hospital. The cases who received PE were set as the PE group, and those who received PE combined with immunoglobulin were set as the PE+immunoglobulin group. The efficacy, clinical score, state of consciousness, immune function, acetylcholine receptor antibody (AChR-Ab), lymphocyte (LYM), albumin (ALB) levels, and the incidence of adverse reactions were compared. Results. The improvement rate was 100.005% in the treatment group and 83.33% in the PE group. After treatment, the clinical score of the PE+immunoglobulin group was lower than that of the PE group, and the clinical relative score of the PE+immunoglobulin group was higher than that of the PE group ( P < 0.05 ). The number of conscious people in the PE+immunoglobulin group was more than that in the PE group ( P < 0.05 ). Immunoglobulin A, immunoglobulin M, immunoglobulin G, and immunoglobulin G in the PE+immunoglobulin group were higher than those in the PE group ( P < 0.05 ). The levels of AChR-Ab and ALB in the PE+immunoglobulin group were higher than those in the PE group, while the level of LYM in the PE+immunoglobulin group was lower than that in the PE group. The incidence of skin system, gastrointestinal system, nervous system, and systemic damage in the PE+immunoglobulin group was lower than that in the PE group ( P < 0.05 ). Conclusion. The treatment of MGC with PE combined with immunoglobulin can not only effectively enhance the consciousness and immune function of patients but also effectively promote the prognosis, and the safety of treatment can be guaranteed.

Independent risk factors for in-hospital outcome of myasthenic crisis: a prospective cohort study

Myasthenic crisis in thymoma-associated myasthenia gravis: a multicenter retrospective cohort study

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: A prospective cohort study

Intensive care due to myasthenia gravis: Risk factors and prognosis

Myasthenic Crisis Treated in a Chinese Neurological Intensive Care Unit: Clinical Features, Mortality, Outcomes, and Predictors of Survival

Predictive Score for In-Hospital Mortality of Myasthenic Crisis: A Retrospective Chinese Cohort Study.

MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation

Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation

Factors Contributing to Myasthenic Crisis after Thymectomy—A Multivariate Analysis Study

The safety and efficacy profile of eculizumab in myasthenic crisis: a prospective small case series

Risk Factors of Myasthenia Crisis after Thymectomy among Myasthenia Gravis Patients

In‐depth Peripheral CD4+ T Profile Correlates with Myasthenic Crisis

Prognostic Analysis of Thymoma-Associated Myasthenia Gravis (MG) in Chinese Patients and Its Implication of MG Management: Experiences from a Tertiary Hospital

Pneumonia and systemic inflammatory response syndrome as predictors for difficult-/prolonged-weaning after invasive ventilation in myasthenic crisis: A retrospective analysis of a Chinese cohort

Predictors of Extubation Failure In Thymomatous Myasthenia Gravis Patient After Thymectomy: Ten Years of Data From A Tertiary Teaching Hospital In Mainland China

Analysis of Mortality and Related Factors in 2195 Adult Myasthenia Gravis Patients in a 10-Year Follow-Up Study

Effects of Plasma Exchange Combined with Immunoglobulin Therapy on Consciousness, Immune Function, and Prognosis in Patients with Myasthenia Gravis Crisis: A Prospective Randomized Test

Clinical outcome and peripheral immune profile of myasthenic crisis with omicron infections: A prospective cohort study

Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series

Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review